Foster Group Inc. Has $1.61 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Foster Group Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 0.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,200 shares of the company’s stock after selling 70 shares during the period. Foster Group Inc.’s holdings in Johnson & Johnson were worth $1,614,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. 4J Wealth Management LLC raised its stake in Johnson & Johnson by 2.2% in the 4th quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock valued at $444,000 after acquiring an additional 62 shares during the period. My Personal CFO LLC increased its position in shares of Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after buying an additional 62 shares during the period. Eagle Strategies LLC increased its position in shares of Johnson & Johnson by 1.8% during the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock valued at $563,000 after buying an additional 63 shares during the period. Clearview Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after buying an additional 64 shares during the period. Finally, Brookmont Capital Management increased its position in shares of Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock valued at $2,328,000 after buying an additional 64 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on JNJ. Morgan Stanley decreased their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Thursday. Bank of America decreased their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, The Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $174.07.

Johnson & Johnson Stock Up 1.5 %

Shares of JNJ opened at $147.77 on Friday. The firm has a market cap of $355.64 billion, a P/E ratio of 9.21, a P/E/G ratio of 2.42 and a beta of 0.53. The stock has a 50 day simple moving average of $148.02 and a two-hundred day simple moving average of $154.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.68 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.